A phase II study of S-1 for the treatment of cytokine and/or tyrosine-kinase inhibitor (TKI) refractory metastatic renal cell carcinoma: Updated results.
Yoshihiko Tomita
Research Funding - Taiho Pharmaceutical
Nobuo Shinohara
No relevant relationships to disclose
Atsushi Mizokami
No relevant relationships to disclose
Masato Fujisawa
No relevant relationships to disclose
Katsuyoshi Hashine
No relevant relationships to disclose
Masaharu Nishikido
No relevant relationships to disclose
Masayuki Nakagawa
No relevant relationships to disclose
Hideyuki Akaza
Consultant or Advisory Role - Taiho Pharmaceutical
Taiji Tsukamoto
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose